BioNJ welcomes The Medicines Company as a new Platinum Member for 2011.
The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. We have three marketed products: Angiomax® (bivalirudin), Cleviprex® (clevidipine) injectable emulsion, and a 50-ml ready-to-use formulation of Argatroban injection. The company also has a pipeline of critical care hospital products in development, including two late-stage development product candidates, cangrelor and oritavancin, as well as two early-stage development product candidates, MDCO-2010 and MDCO-216.
BioNJ welcomes BioLeap and ThromboGenics as new Core Members for 2011.
BioLeap is a molecular discovery and design company driven by proprietary, next-generation computational fragment-based design (CFBD) technology. We create new chemical entities, molecularly tailored to modulate a particular protein target. BioLeap changes the paradigm for identifying chemical starting points and for deciding which compounds to make next during lead optimization, obviating the need for costly high throughput screening (HTS). BioLeap’s process creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents, and generates fast-follower compounds for early market entry.
ThromboGenics (Euronext Brussels: THR) is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease, and cancer. Our lead product, ocriplasmin, has completed two successful phase III clinical trials for the pharmacologic treatment of symptomatic vitreomacular adhesions, including macular holes, a common source of vision loss in the elderly. It will be submitted to the FDA during 4Q 2011, and ThromboGenics will commercialize this product via its own dedicated organization based in Iselin, NJ.
BioNJ welcomes Stevens Institute of Technology as a new Institutional Member for 2011.
Founded in 1870, Stevens is a premier private coeducational institution focused on research and entrepreneurship. Stevens is committed to exploring the frontiers of engineering, science, and management. Three schools and one college support the mission of the Institute. Creative and entrepreneurial research is an integral part of the Stevens mission. This is expressed through the concept of Technogenesis, a novel educational approach pioneered by the Institute. Technogenesis leverages the expertise of students, faculty, and colleagues in industry to conceive, design, and commercialize new technologies. Stevens’ 2008 ranking by Forbes magazine as the nation’s third Top-Patent-Revenue-Generating University underscores the success of this endeavor.
BioNJ thanks Deloitte for renewing its Platinum Membership for 2011.
Deloitte is a leading provider of audit, consulting, financial advisory, risk management, and tax services for life science and biotechnology client to shape the evolution of the industry. Through their dedication to being a catalyst for innovation, Deloitte identifies and explores emerging opportunities on the edge of business and technology.
BioNJ thanks Chromocell Corporation, Ezose Sciences, and Roka Bioscience for renewing as Core Members for 2011.
Chromocell is a drug discovery company focused on the identification and development of novel therapeutics against the most complex and challenging drug targets. The company focuses on high-value drug targets and works mainly in pain relief, anxiety treatment, and respiratory disorders.
Ezose Sciences, Inc., is pioneering a novel high-throughput solution that allows for the rapid and efficient analyses of glycans present in human blood and other tissues.
Roka Bioscience, Inc., is a molecular diagnostics company offering highly accurate, cost-effective, easy-to-use molecular assays for biopharmaceutical production, water and food safety testing. In addition to biopharmaceutical, water and food safety testing, Roka Bioscience is in a position to pursue other industrial applications in the future, including veterinary, environmental bioterrorism, and infection control. Established in 2009, Roka’s mission is to become a global leader in molecular diagnostics for industrial applications. Armed with a portfolio of time-tested diagnostic assays applied through innovative automated delivery platforms, Roka’s technology is positioned to be the gold standard for industrial diagnostics.
BioNJ thanks BioReppository Resources, JBK Associations, and JFK Communications for renewing as Associate Members for 2011.
BioRepository Resources (BRR) is a privately held life sciences service provider located in northern New Jersey. It is owned and operated by Catherine Chin and Glenn Bullett. The principals have a combined 35-plus years in the pharmaceutical and contract research environments in Canada and the United States. This experience has laid the groundwork for a client-focused approach to the contract pharmaceutical service business.
Our sole objective is to provide life sciences companies with a reliable, secure, and economical alternative for all of their offsite biological sample storage requirements.
All biorepository activities are conducted under Good Laboratory Practices (GLP) and governed by Standard Operating Procedures and regular quality control reviews. Internal back-up systems are in place for all aspects of the business. Repositories of biological samples and their inventory databases are critical and important components of pharmaceutical research. This is highly respected at BRR, and our facility is managed with the utmost regard for “The Best Practices for Repositories.”
JBK Associates, Inc., is a retainer-based, award-winning, and woman-owned certified executive search firm with a strong focus on the life sciences and healthcare industries. Placing superstar talent in a wide array of functional specialties, JBK Associates, an AESC member, takes a fully integrated talent management approach to help all size organizations achieve major growth by providing best-in-class solutions for search, staffing, and organizational development. The firm has been recognized by Forbes, The American Business Awards, Diversity Business, Working Mother, Pharma Voice, and New Jersey Business for its achievements and track record of success.
JFK Communications is a healthcare public relations firm that partners with specialty pharmaceutical, biotechnology, and medical technology companies. If you need a strategic communications firm whose knowledge is exceeded only by its passion, we’re ready to help.